CLINICAL RESEARCH

e-ISSN 1643-3750 © Med Sci Monit, 2019; 25: 8011-8018 DOI: 10.12659/MSM.919366

 Received:
 2019.08.13

 Accepted:
 2019.10.15

 Published:
 2019.10.25

Mar

Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study

Authors' Contribution: Study Design A Data Collection B Statistical Analysis C Data Interpretation D anuscript Preparation E Literature Search F Funds Collection G	DEF 1 C 1 C 3 B 2 BE 1 ADE 4 ACDE 1,5	Yan-Ming Li* Chao Jiang* Liu He Xin-Xu Li Xiao-Xia Hou San-Shuai Chang Gregory Y.H. Lip Xin Du Jian-Zeng Dong	 Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing, P.R. China Department of Cardiology, Beijing Tongren Hospital, Capital Medical University, Beijing, P.R. China Chinese Center for Disease Control and Prevention, Beijing, P.R. China Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, U.K. Heart Health Research Center, Beijing, P.R. China Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China 			
	AG 1	Chang-Sheng Ma				
Correspondin Source o	g Authors: f support:	from the National Science Foundation of China (81530016), su	xinheart@sina.com (2016YFC0900901, 2017YFC0908803, 2018YFC1312501), a grant upported this work. Grants from Bristol-Myers Squibb (BMS), Pfizer, orsed the development of the China Atrial Fibrillation Registry			
Bac Material/I	kground: Methods:	able in Chinese AF patients. We compared symptoms, quality of life (QoL), and tre	ies in atrial fibrillation (AF). However, limited data is avail- eatment of AF according to sex from the China AF Registry			
Con	study. Results: We studied 14 723 patients with non-valvular AF, of whom 5645 patients (38.3%) were female. Wom older than men (67.5±10.6 vs. 62.2±12.2). Compared to men, women had more comorbidities and proportion of CHA2DS2-VASc score ≥2. Women with AF experienced more severe or disabling sympto men (33.7% vs. 22.9% in age <75 group; 40.3% vs. 28.7% in age ≥75 group; both P<0.0001). After mul analysis, women with AF still had lower QoL (OR 0.69; 95%CI, 0.63–0.76; P<0.0001). Women tended lower rates of ablation and rhythm-control drug use in those aged <75 years. Oral anticoagulant use and had no sex difference in AF patients with a CHA2DS2-VASc score ≥2. Conclusions: In Chinese AF patients, women were older and more symptomatic, and had worse QoL. Despite all th ferences, women tended to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant is control to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant is control to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant is control to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant is control to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant is control to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant is control to receive less rhythm-control treatment in those aged <75 years.					
		was substantially underused in high stroke risk patients, regardless of sex. Clinical Trial Registration: URL: http://www.chictr.org.cn/showproj.aspx?proj=5831. Unique identifier: ChiCTR-OCH-13003729 Atrial Fibrillation • Quality of Life • Sex Characteristics • Therapeutics				
MeSH Ke	., words:	Actian ribilitation - Quality of Life - Sex clididte	nates - metapeutes			
Full-	text PDF:	https://www.medscimonit.com/abstract/index/idArd	2/919366			
		🖹 2049 🏛 2 🍱 4 📑	ä 35			



MEDIC SCIENCE MONITOR

Background

Atrial fibrillation (AF), the most common arrhythmia, affected more than 33 million individuals in 2010 worldwide. It increases the burden of stroke, heart failure, cognitive decline, and mortality [1,2]. Sex-related disparities in AF are increasingly acknowledged [3–5]. Western countries have reported that clinical presentations and quality of life (QoL) differed between women and men with AF [6–8], and women with AF seemed to be under-treated compared to men [8–10]. However, sex differences are not well-examined in Chinese AF patients.

The China AF Registry study is an ongoing prospective registry – one of the largest for Asian AF patients. It will provide an excellent opportunity to evaluate this knowledge gap. A better understanding of the sex differences in AF may have important implications for quality improvement to reduce or even eliminate the sex disparities in AF care.

In this study, we used data from the China AF Registry to evaluate sex-related differences with the presentation, QoL, and treatment in Chinese AF patients.

Material and Methods

The China AF Registry study is a prospective, multicenter, ongoing registry study of AF patients from 31 hospitals in Beijing, China. The design of the study had been published [11]. Local ethics committee approval was obtained and all participants provided signed informed consent.

Study population

The China AF Registry study had enrolled 19 515 AF patients from August 2011 to December 2016. In this analysis, we excluded 546 patients with mitral stenosis or valvular surgery, 3380 patients without valid Atrial Fibrillation Effects on QualiTy of Life (AFEQT) questionnaires, and 866 patients without European Heart Rhythm Association (EHRA) classification data. Finally, we included 14 723 participants. Figure 1 shows a flowchart of the study.

Data collection

Clinicians in participating hospitals collected data from medical charts. Collecting information included necessary socio-demographic data, AF type and duration, medical history, symptom and AFEQT questionnaires, and previous and current treatment. We defined variables according to the ACC/AHA recommendations on AF clinical data standards [12].




Figure 1. Flowchart of patients included. AF – atrial fibrillation; AFEQT – Atrial Fibrillation Effects on QualiTy of Life; EHRA = European Heart Rhythm Association.

AF symptoms and QoL evaluation

AF-related symptoms were evaluated using the EHRA AF symptom classification: no symptoms (EHRA I), mild symptoms (EHRA II), severe symptoms (EHRA III), and disabling symptoms (EHRA IV) [13].

A Chinese version of the AFEQT questionnaire was collected to assess health-related quality of life (HRQoL) at baseline. The AFEQT questionnaire is an AF-specific QoL evaluation which was recently developed and validated, supporting its use as a self-administered outcome measure in studies and as a tool for disease management [14]. The AFEQT questionnaire contains 20 questions to evaluate the influence of AF on patients' HRQoL during the past 4 weeks. The 18 items generate 3 individual subscales - Symptoms, Daily Activities, and Treatment Concern. The last 2 indicate the Treatment Satisfaction domain. Overall AFEQT score is calculated based on the first 3 functional subscales. To be valid, the AFEQT questionnaires must have should at least half of the questions answered for each domain. AFEQT is scored with a 7-point Likert scale. The range of overall AFEQT or subscale scores is 0-100. Score 0 represents extremely disability and 100 indicates not at all limited. Thus, higher ratings indicate a better health status. For a percentage grading system of AFEQT scores, we set ≥60 as passing scores indicating a 'normal level' of QoL, and the lower score sections as mild impairment of QoL (AFEQT scores 40-59), moderate impairment of QoL (AFEQT scores 20-39) and severe impairment of QoL (AFEQT <20).


Statistical analysis


Continuous variables showed a mean \pm standard deviation or median (interquartile range); differences were assessed using the *t* test or Wilcoxon rank-sum test. Categorical variables are

Table 1. Baseline characteristics according to sex and age.

	Age <75 (N=11515)			Age ≥75 (N=3208)		
Characteristics	Female N=4053	Male N=7462	<i>P</i> value	Female N=1592	Male N=1616	P value
Age (years)	62.8±8.6	58.5±10.1	<0.0001	79.5±3.8	79.2±4.0	0.068
Health insurance coverage						
	300/4053	512/7462		95/1592	65/1616	
None	(7.4)	(6.9)	<0.0001	(6.0)	(4.0)	<0.000
	1729/4053	2510/7462		781/1592	673/1616	
Low	(42.7)	(33.6)		(49.1)	(41.7)	
11:ab	2024/4053	4440/7462		716/1592	878/1616	
High	(49.9)	(59.5)		(45.0)	(54.3)	
Completed high school	839/3824	2875/7109	<0.0001	320/1411	548/1441	<0.0001
	(21.9)	(40.4)		(22.7)	(38.0)	
BMI	25.6±4.0	25.9±3.4	<0.0001	24.6±4.0	24.2±3.3	0.001
Smoking	76/4042	2244/7441	<0.0001	41/1579	179/1605	<0.000
	(1.9)	(30.2)		(2.6)	(11.2)	
Drinking	60/4045	2832/7428	<0.0001	17/1578	277/1605	<0.000
	(1.5)	(38.1)		(1.1)	(17.3)	
Medical History						
Heart failure	502/4053	746/7462	<0.0001	561/1592	472/1615	0.0003
	(12.4)	(10.0)		(35.2)	(29.2)	
Hypertension	2651/4052	4135/7458	<0.0001	1319/1589	1215/1615	<0.0001
	(65.4)	(55.4)		(83.0)	(75.2)	
Diabetes mellitus	987/4052	1611/7460	0.001	526/1592	454/1615	0.002
	(24.4)	(21.6)		(33.0)	(28.1)	
Previous stroke/TIA/SE	550/4051 (13.6)	993/7455 (13.3)	0.699	397/1589 (25.0)	424/1614 (26.3)	0.405
	520/4050	1059/7455	0.042	398/1588	458/1612	0.032
Vascular disease	(12.8)	(14.2)		(25.1)	(28.4)	
	170/4051	321/7455	0.782	101/1589	114/1613	0.421
Previous bleeding	(4.2)	(4.3)		(6.4)	(7.1)	
	1290/4043	2075/7448	<0.0001	602/1587	477/1608	<0.0001
Hyperlipidemia	(31.9)	(27.9)		(37.9)	(29.7)	
eGFR <60 mL/min/1.73 m ²	110/3180	79/5919	(0.0001	185/1308	111/1317	<0.000
eGFR <60 mL/min/1./3 m ²	(3.5)	(1.3)	<0.0001	(14.1)	(8.4)	
AF type						
Neulu diamagad	232/4050	286/7455		151/1591	151/1616	0 5 2 6
Newly diagnosed	(5.7)	(3.8)	<0.0001	(9.5)	(9.3)	0.528
Paroxysmal	2643/4050	4163/7455		774/1591	757/1616	
	(65.3)	(55.8)		(48.7)	(46.8)	
Persistent	1175/4050	3006/7455		666/1591	708/1616	
	(29.0)	(40.3)		(41.9)	(43.8)	
AF duration (years)	2.4	2.5	0.052	3.0	3.6	0.001
· · · · · · · · · · · · · · · · · · ·	(0.6–5.7)	(0.7–6.0)		(0.8–7.3)	(1.0–9.0)	
CHA ₂ DS ₂ -VASC	700//0000	4072 /7450				
0 or 1	722/4050	4073/7452	<0.0001	0	0	-
	(17.8)	(54.7)		1500/1500	1(12/1(12	
≥2	3328/4050 (82.2)	3379/7452 (45.3)		1588/1588 (100)	1612/1612 (100)	

Values are n/N (%), mean \pm SD or median (IQR). Denominators may be subject to missing data. BMI – body mass index; TIA – transient ischemic attack; SE – systemic embolism; eGFR – estimated glomerular filtration rate; AF – atrial fibrillation; IQR – interquartile range; CHA₂DS₂-VASc – cardiac failure or dysfunction, hypertension, age \geq 75 years (doubled), diabetes mellitus, stroke (doubled)–vascular disease, age 65–74 years, and sex category (Female).





shown as numbers (percentages), and differences were compared using the chi-square test.

Multivariate logistic regression analysis was performed to assess the association between sex and QoL (the proportion of overall AFEQT score \geq 60). We corrected variables with potential influence on QoL, including age, body mass index (BMI), medical insurance and education, smoking, comorbidities (heart failure, hypertension, diabetes, previous thromboembolism, vascular disease, hyperlipidemia, and renal dysfunction), AF type and duration, and current pharmacological treatments.

A two-tailed *P* value <0.05 was considered statistically significant. We used SAS software 9.2 for data analyses.

Results

Among 14 723 patients with AF included in this study, 5645 (38.3%) were women. Table 1 shows the characteristics of the patients. Since women were older on average by 5 years than men in the study (67.5±10.6 vs. 62.2±12.2, P<0.0001), we stratified the patients by age<75 and age \geq 75 groups. In both age groups, women had higher rates of heart failure, hypertension, diabetes, and renal dysfunction, but a lower rate of vascular disease. Previous thromboembolism was similar according to sex in both 2 age groups. Paroxysmal AF (65.3% vs. 55.8%, P<0.0001) and a CHA₂DS₂-VAS_c score \geq 2 (82.2% vs. 45.3%, P<0.0001) was more prevalent in women for those aged <75 years.

AF-related symptoms

Female AF patients experienced more severe or disabling symptoms, with a higher proportion of EHRA III and IV classification, than men (35.6% vs. 24.0%, P<0.0001). Only 5.4% of women had no symptom, compared with 8.4% of men (Figure 2). Both age groups had similar results.

Quality of life

Figure 3 summarizes the proportion of the overall and each subscale of AFEOT scores by sex and age. Women had a lower percentage of an average QoL level (AFEQT ≥60 scores) than men (54.1% vs. 66.7% in overall patients, 57.0% vs. 68.5% in age <75 years group and 46.8% vs. 58.4% in those aged ≥75 years group, both P<0.0001). The subscales of Symptoms, Daily Activities, and Treatment Concern all showed consistent results (Figure 3). We also compared the mean value of overall AFEQT and each subscale score by sex, type of AF, and CHA₂DS₂-VASc scores, as shown in Figure 4. Women had lower overall AFEQT scores than men in those aged <75 years (59.6±15.0 vs. 64.4±14.2, P<0.0001) and in older groups (57.5±15.1 vs. 61.2±15.3, P<0.0001). In newly diagnosed, paroxysmal AF, or persistent AF, women had lower overall AFEQT scores than men (All P < 0.05 except for newly diagnosed AF in age \geq 75 years group). Also, the AFEQT scores decreased in women across all CHA, DS,-VASc score groups. After the correction of demographics, comorbidities, and pharmacological treatments, female sex remained independently associated with lower overall AFEQT score (OR 0.69; 95%CI, 0.63-0.76; P<0.0001).

AF-related treatment

We found no sex disparity in the prior use of electrical cardioversion (Table 2). Women tended to receive less AF ablation (5.7% vs. 6.7%, P=0.025) in those aged <75 years, but not in patients age \geq 75 years (2.0% vs. 2.0%, P=0.949). In the group age <75, women were more likely to receive the rate control (51.4% vs. 46.9%, P<0.0001), but fewer received rhythm-control drugs (35.5% vs. 39.8%, P<0.0001). However, in the elderly group, current rhythm-control drug use had no significant difference between women and men (20.2% vs. 20.9%, P=0.664), while women still were more likely to receive rate control therapy (65.2% vs. 59.3%, P=0.001). Both women and men with CHA₂DS₂-VASc score \geq 2 had low rates of oral anticoagulant (OAC) use (32.1% vs. 30.1% in those aged <75, P=0.081; and 34.6% vs. 35.3% in those aged \geq 75, P=0.700).

Discussion

This massive Chinese AF cohort study indicated that women with AF tended to be older, with more comorbidities and




Figure 3. Proportions of each section in overall AFEQT and subscales scores by sex. AFEQT scores were classified as 4 sections: normal level of QoL (AFEQT scores ≥60), mild impairment of QoL (AFEQT scores 40~59), moderate impairment of QoL (AFEQT scores 20~39), and severe impairment of QoL (AFEQT <20). (A) Overall patients; (B) Patients aged <75 years old; (C) Patients aged ≥75 years old. AFEQT – Atrial Fibrillation Effects on QualiTy of Life; SY – symptoms; DA – daily activities; TC – treatment concern; TS – treatment satisfaction; F – Female; M – Male. * P<0.0001, ** P=0.025, *** P=0.01, Female vs. Male.

more severe symptoms. After adjustment, women had lower QoL than men. Moreover, despite being much more likely to be symptomatic, women tended to receive less rhythm-control treatment in those aged <75. OAC use was low and had no sex difference in high stroke risk AF patients.

Prior extensive cohort studies have shown sex disparities in clinical features, treatment, and outcomes of AF in Western countries [6,7]. Female AF patients tended to be older, and were more likely to have a high burden of hypertension and heart failure with a preserved ejection fraction [15]. However, few studies have reported the association between sex and symptoms burden and QoL [8,16,17]. In a European survey, the EORP-AF study, women were found to have more symptoms, including palpitations, fear, and anxiety [7]. A systematic review suggested that asymptomatic AF was less common among women than among men [18]. A Europe survey reported that women had a lower general QoL using EuroQol

scores [8]. The ORBIT-AF registry [6], a US-based observational study, has demonstrated that female AF patients had more significant impairment of HRQoL as measured by specific AFEQT scores. Such sex differences were consistent with our large cohort study of Chinese AF patients, and a recently published systemic review has confirmed this [19]. The physical and psychosomatic characteristics of female patients may be related to the observed differences in clinical characteristics and presentation [20–24]. Older age may also contribute to the differences in comorbidities, since women were older by an average of 5 years compared with men [20]. However, the differences in QoL were still significant after multivariable adjustment.

Guidelines indicate rhythm-control therapy to improve the symptom of AF patients (Class I, level B) [25]. In our study, younger (age <75) female AF patients were treated more conservatively with less catheter ablation or antiarrhythmic drugs than men, despite having a higher proportion of paroxysmal AF,

Trochroot	Age <75 (N=11515) n (%)			Age ≥75 (N=3208) n (%)		
Treatment	Female (N=4053)	Male (N=7462)	<i>P</i> value	Female (N=1592)	Male (N=1616)	<i>P</i> value
Prior electrical cardioversion	76 (1.9)	178 (2.4)	0.075	10 (0.6)	15 (0.9)	0.334
Prior AF catheter ablation	230 (5.7)	503 (6.7)	0.025	32 (2.0)	33 (2.0)	0.949
Current rhythm-control drugs	1437 (35.5)	2970 (39.8)	<0.0001	332 (20.9)	327 (20.2)	0.664
Propafenone	757 (18.7)	1213 (16.3)	0.001	108 (6.8)	116 (7.2)	0.661
Amiodarone	564 (13.9)	1621 (21.7)	<0.0001	157 (9.9)	171 (10.6)	0.501
Sotalol	90 (2.2)	128 (1.7)	0.058	26 (1.6)	20 (1.2)	0.346
Current rate control drugs	2083 (51.4)	3502 (46.9)	<0.0001	1038 (65.2)	959 (59.3)	0.001
β-blocker	1921 (47.4)	3232 (43.3)	<0.0001	895 (56.2)	807 (49.9)	<0.0001
Calcium-channel blockers	199 (4.9)	270 (3.6)	0.001	138 (8.7)	107 (6.6)	0.029
Digoxin	252 (6.2)	384 (5.1)	0.016	234 (14.7)	201 (12.4)	0.062
* Current OAC(CHA ₂ DS ₂ -VASC \geq 2)	1002/3328 (30.1)	1084/3379 (32.1)	0.081	560/1588 (35.3)	558/1612 (34.6)	0.700

 Table 2. AF-related treatment stratified by sex and age.

Values are n (%), except where indicated. * Rates of current OAC are expressed as the number of patients received oral anticoagulant treatment divided by the number of patients who have indication for anticoagulation treatment (i.e., CHA_2DS_2 -VAS_c ≥ 2). AF – atrial fibrillation; OAC – oral anticoagulant; CHA_2DS_2 -VAS_c – cardiac failure or dysfunction, hypertension, age ≥ 75 years (doubled), diabetes mellitus, stroke (doubled)–vascular disease, age 65–74 years, and sex category (Female).

more severe AF-related symptoms, and worse QoL. The ORBIT-AF study did not find sex-specific differences in the use of antiarrhythmic drugs [6], but women tended to receive less electric cardioversion or ablation therapy. The EORP-AF study reported similar differences in treatment [7]. Women with symptomatic AF received less rhythm-control treatment, and we observed the same treatment pattern in asymptomatic patients.

Nevertheless, these studies did not adjust for some critical factors, including age, comorbidities, duration, and symptom burden of AF. The reasons for the disparities remain mostly unknown, and potential explanations include sex differences in patient preferences and other clinical and socioeconomic factors [26]. Age may play an essential role in treatment strategy referral [15]. In our study, there was no sex-specific difference in rhythm-control treatment for patients \geq 75 years. The efficacy and safety of antiarrhythmic drugs for women may influence the treatment preferences [27–29]. In addition, women tended to be less educated and less covered by health insurance than men in our study. Thus, they may be more likely to delay seeking medical care and to accept more conservative treatment than men.

Our study observed that OAC for preventing stroke in high-risk patients was substantially underused regardless of sex, and women received OAC use similarly to men. Previous substantial worldwide cohort research reported no sex differences in the use of OAC [30,31]. The EORP-AF and ORBIT-AF study found similar results [6, 7]. However, in another outpatient AF cohort, with a CHA_2DS_2 -VASc score ≥ 2 , women were associated with less frequent prescription of OAC [32]. Although the previous research suggested that female sex is not an independent risk factor of thromboembolism [33], women had poorer long-term outcomes among stroke survivors [34,35]. The extensive treatment gap in OAC use for stroke prevention remains in Chinese AF patients of both sexes. Therefore, great efforts are warranted to promote OAC therapy among highrisk patients with AF in China.

Limitations

First, the China AF Registry is a hospital-based registry; thus, patient selection bias is possible. Women may tend to not seek medical help until they experienced severe symptoms and significantly impaired QoL. However, these patients are representative of the patients we meet in clinical practice and thus are clinically relevant. Second, participating hospitals in this study are in Beijing, China's capital; however, about half of the participants came from all over the country, thus increasing the population samples' representativeness. Finally, statistical methods cannot adequately correct for residual or unmeasured confounders in a registry study.




Figure 4. Mean overall AFEQT and subscales scores by sex and type of AF and CHA₂DS₂-VAS_c Scores between females and males.
(A) Mean overall AFEQT and subscales scores by sex; (B) Mean overall AFEQT and subscales scores by sex and type of AF.
(C) Mean overall AFEQT and subscales scores by sex and CHA₂DS₂-VAS_c scores. AFEQT – Atrial Fibrillation Effects on QualiTy of Life; SY – symptoms; DA – daily activities; TC – treatment concern; TS – treatment satisfaction. * P<0.0001, ** P<0.05, Female vs. Male.

Conclusions

In this prospective Chinese Registry, women with AF tended to be older, with more comorbidities, and had more severe symptoms and poorer QoL, compared to men. Despite all these factors, women tended to receive less rhythm-control treatment than men in those aged <75 years. OAC was substantially underused in high stroke risk patients regardless of sex.

Disclosures

Dr. Jian-Zeng Dong received honoraria for giving lectures from Johnson & Johnson.

Dr. Chang-Sheng Ma received honoraria for giving lectures from Bristol-Myers Squibb (BMS), Pfizer, Johnson & Johnson, Boehringer Ingelheim (BI), and Bayer.

References:

- 1. Chugh SS, Havmoeller R, Narayanan K et al: Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation, 2014; 129: 837–47
- 2. Healey JS, Oldgren J, Ezekowitz M et al: Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: A cohort study. Lancet, 2016; 388: 1161–69
- 3. Ko D, Rahman F, Schnabel RB et al: Atrial fibrillation in women: Epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol, 2016; 13: 321–32
- 4. Ko D, Rahman F, Martins MA et al: Atrial fibrillation in women: treatment. Nat Rev Cardiol, 2017; 14: 113–24
- Gillis AM: Atrial fibrillation and ventricular arrhythmias: Sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes. Circulation, 2017; 135: 593–608
- 6. Piccini JP, Simon DN, Steinberg BA et al: Differences in clinical and functional outcomes of atrial fibrillation in women and men: Two-year results from the ORBIT-AF registry. JAMA Cardiol, 2016; 1: 282–91
- Lip GY, Laroche C, Boriani G et al: Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015; 17: 24–31
- Dagres N, Nieuwlaat R, Vardas PE et al: Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol, 2007; 49: 572–77
- 9. Kassim NA, Althouse AD, Qin D et al: Gender differences in management and clinical outcomes of atrial fibrillation patients. J Cardiol, 2017; 69: 195–200
- Bhave PD, Lu X, Girotra S et al: Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm, 2015; 12: 1406–12
- 11. Du X, Ma C, Wu J et al: Rationale and design of the Chinese Atrial Fibrillation Registry Study. BMC Cardiovasc Disord, 2016; 16: 130
- 12. McNamara RL, Brass LM, Drozda JP Jr. et al: ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation, 2004; 109: 3223–43
- 13. Kirchhof P, Auricchio A, Bax J et al: Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace, 2007; 9: 1006–23
- 14. Spertus J, Dorian P, Bubien R et al: Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol, 2011; 4: 15–25
- Schnabel RB, Yin X, Gona P et al: 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet, 2015; 386: 154–62
- Paquette M, Roy D, Talajic M et al: Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol, 2000; 86: 764–68
- Dorian P, Paquette M, Newman D et al: Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J, 2002; 143: 984–90

Dr. Lip was a consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo, and was a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees were directly received personally.

Other authors declare no conflict of interest.

- Xiong Q, Proietti M, Senoo K, Lip GY: Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol, 2015; 191: 172–77
- Stromnes LA, Ree H, Gjesdal K, Ariansen I: Sex differences in quality of life in patients with atrial fibrillation: A systematic review. J Am Heart Assoc, 2019; 8: e010992
- Humphries KH, Kerr CR, Connolly SJ et al: New-onset atrial fibrillation: Sex differences in presentation, treatment, and outcome. Circulation, 2001; 103: 2365–70
- 21. Kerr CR, Humphries K: Gender-related differences in atrial fibrillation. J Am Coll Cardiol, 2005; 46: 1307–8
- 22. Khairy P, Nattel S: New insights into the mechanisms and management of atrial fibrillation. CMAJ, 2002; 167: 1012–20
- Akintade BF, Chapa D, Friedmann E, Thomas SA: The influence of depression and anxiety symptoms on health-related quality of life in patients with atrial fibrillation and atrial flutter. J Cardiovasc Nurs, 2015; 30: 66–73
- Ball J, Carrington MJ, Wood KA, Stewart S: Women versus men with chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). PLoS One, 2013; 8: e65795
- 25. Kirchhof P, Benussi S, Kotecha D et al: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016; 37: 2893–962
- 26. Weberndorfer V, Beinart R, Ricciardi D et al: Sex differences in rate and rhythm control for atrial fibrillation. Europace, 2019; 21(5): 690–97
- Higgins AY, Waks JW, Josephson ME: Influence of gender on the tolerability, safety, and efficacy of quinidine used for treatment of supraventricular and ventricular arrhythmias. Am J Cardiol, 2015; 116: 1845–51
- Makkar RR, Fromm BS, Steinman RT et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA, 1993; 270: 2590–97
- Moller M, Torp-Pedersen CT, Kober L: Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congest Heart Fail, 2001; 7: 146–50
- 30. Lip GY, Rushton-Smith SK, Goldhaber SZ et al: Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes, 2015; 8: S12–20
- Mazurek M, Huisman MV, Rothman KJ et al: Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program. Am J Med, 2018; 131: 945–55e3
- Hsu JC, Maddox TM, Kennedy K et al: Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol, 2016; 67: 2913–23
- 33. Lan DH, Jiang C, Du X et al: Female sex as a risk factor for ischemic stroke and systemic embolism in Chinese patients with atrial fibrillation: A report from the China-AF study. J Am Heart Assoc, 2018; 7: e009391
- Martin RC, Burgin WS, Schabath MB et al: Gender-specific differences for risk of disability and death in atrial fibrillation-related stroke. Am J Cardiol, 2017; 119: 256–61
- Hong Y, Yang X, Zhao W et al: Sex differences in outcomes among stroke survivors with non-valvular atrial fibrillation in China. Front Neurol, 2017; 8: 166